Page 79 - FINAL PROGRAM
P. 79
TUESDAY, 5 JULY 2016
10:00 - 11:30 Room 101
Session 35: AMH: The plot thickens
10:00 O-129
10:15 O-130
10:30 O-131 10:45 O-132 11:00 O-133
11:15 O-134
The bone morphogenetic protein 15 up-regulates the anti-Müllerian hormone receptor expression in granulosa cells
N. di Clemente (France)
Comparable inter-laboratory performance of two automated platforms (Roche® and Beckman Coulter®) for Anti-Müllerian Hormone (AMH) evaluation permits greater clinical con dence when assessing functional ovarian reserve
C. Fairbairn (United Kingdom)
Unraveling the long-term decline of anti-Müllerian hormone
A. de Kat (The Netherlands)
Anti-Müllerian hormone levels and features of polycystic ovary syndrome in adolescence
M. Caanen (The Netherlands)
Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM)
P. Bhide (United Kingdom)
Irrespective of age, serum Anti-Müllerian hormone (AMH) levels are related to miscarriage rates in IVF-ET thereby supporting the hypothesis that AMH is a qualitative biomarker
B. Tarasconi (France)
FINAL PROGRAMME I HELSINKI, FINLAND – 3 TO 6 JULY 2016 75
SCIENTIFIC PROGRAMME TUESDAY, 5 JULY
